Pharma cos eye buyouts in US, Europe

  • 1:46
  • Published On: September 01, 2008
Cinema View
Embed
Strong earnings and a weak dollar could prompt Indian drug makers to look carefully at the US and European pharma space as the markets there looks ripe for acquisition. According to Bradford Crutchfield, VP, Bio-Rad Laboratories USA, it is a great time for Indian companies to look at the US and Europe especially for niche segments which they might not be good at.

Related Videos

"If Government Action Was Enough, Why Is WHO Still Flagging Indian-Made Drugs?" Asks Expert
August 13, 2023 7:12
WHO Alert For Indian Drug, 5th In 10 Months: 'Jan Vishwas', The Law We Need?
August 13, 2023 24:21
"Chemicals Within Safe Limits": Indian Firm After WHO Flags Syrup In Iraq
August 08, 2023 1:55
Sun Pharma Q4 Profit In Line With Estimates
May 26, 2023 0:35
"No Contamination Found": Tamil Nadu Official As US Flags Indian Eye Drop
April 04, 2023 2:17
Drug Major Sun Pharma Hit By Ransomware Attack
March 27, 2023 1:53
2 Dead, 2 Injured In Explosion At Gujarat Pharma Company
February 28, 2023 1:32
Late Night Inspection At Chennai Firm Linked To Vision Loss, Death In US
February 04, 2023 2:23
Top Headlines Of The Day: February 4, 2023
February 04, 2023 1:52
The Biggest Stories Of February 3, 2023
February 03, 2023 20:49
Indian Company Recalls Eyedrops Linked To Infection Death In US
February 03, 2023 3:08
Finance Minister Announces New Programme To Promote Research In Pharma
February 01, 2023 0:43
Our Offerings: NDTV
  • मध्य प्रदेश
  • राजस्थान
  • इंडिया
  • मराठी
  • 24X7
Choose Your Destination